Difference between revisions of "Chlorambucil (Leukeran)"

Revision as of 18:24, 31 July 2019

General information

Class/mechanism: Nitrogen mustard, alkylating agent. Interferes with DNA replication and induces apoptosis through accumulation of p53 in the cytosol and downstream activation of the apoptosis promoter Bax.^[1]^[2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

3/18/1957: Initial FDA approval

Also known as

Brand names: Chloraminophene, Chlorambusil, Chlorobutin, Chlorbutin, Leukeran, Linfoxan

References

[insert-1] 1.0 ^1.1 Chlorambucil (Leukeran) package insert

[2] Chlorambucil (Leukeran) package insert (locally hosted backup)

[3] Chlorambucil (Leukeran) patient drug information (Chemocare)

[4] Chlorambucil (Leukeran) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 7: / Line 7: @@
 ==Diseases for which it is used==
-*[[Chronic lymphocytic leukemia (CLL/SLL)]]
+*[[Chronic lymphocytic leukemia]]
 *[[Hodgkin lymphoma]]
 *[[Follicular lymphoma]]